Creative Tech's Next Wave
Design software leader Figma has increased its IPO price range, signaling strong investor confidence in the creative tech space. This successful public offering could create positive momentum for other companies specializing in collaborative and digital creation tools.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Figma's successful IPO with an increased valuation to nearly $19 billion demonstrates strong investor appetite for creative tech and collaborative software. This momentum could lift other companies in the digital creation ecosystem, from design tools to enterprise collaboration platforms.
What You Need to Know
This group focuses on companies that power digital creation and enterprise collaboration through subscription-based software models. These firms typically serve businesses with essential tools for design, project management, and workflow automation, offering steady recurring revenue streams.
Why These Stocks
These companies were handpicked by professional analysts as key players in the digital creation value chain. They represent firms that could benefit from the positive market sentiment surrounding creative tech following Figma's strong public market debut.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+61.95%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 61.95% over the next year.
Stocks Rated Buy by Analysts
12 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
IPO Momentum Building
Figma's successful IPO with increased valuation shows strong investor appetite for creative tech. This positive sentiment could lift other companies in the digital creation space.
AI-Powered Innovation Wave
These companies are at the forefront of AI-enhanced creative tools and collaborative software. As businesses increasingly adopt digital-first workflows, demand for these solutions continues growing.
Subscription Revenue Stability
Most of these firms operate on recurring subscription models, providing predictable revenue streams. This business model has proven resilient and attractive to investors seeking steady growth.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Unlock all the stocks in this group on Nemo
Sign up free to view all stocks in this group and never miss out on another investment opportunity with Nemo.
Sign up in 60 seconds
Zero commission trading
SIPC-protected up to $500,000
Backed by Exinity Group
6% AER interest on uninvested cash, paid out daily
AI investment insights
Discover More Opportunities
The Apple Card Shake-Up: A New Financial Partnership
JPMorgan Chase is reportedly taking over as the issuer for the Apple Card, replacing Goldman Sachs in a major financial partnership shift. This development could create opportunities for other payment processors and financial institutions involved in the co-branded credit card market.
The Apple Card Shake-Up: A New Financial Alliance
JPMorgan Chase is poised to become the new issuer for the Apple Card, taking over from Goldman Sachs in a landmark deal. This shift in financial partnerships creates potential ripple effects for payment networks and the broader fintech infrastructure supporting them.
Beyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Frequently Asked Questions
Everything you need to know about the product and billing.